Collect of Cord Blood From Subjects at Risk for Sickle Cell Disease, for the Purpose of Laboratory Research

Institut National de la Santé Et de la Recherche Médicale, France44 enrolled

Overview

The study consists in collecting umbilical cord blood cells from newborns at risk of sickle cell disease, to perform laboratory experiments aiming to characterize the cells with HbS/HbS mutation, to develop methods to prepare, to gene-modify and to preserve these cells.

Pregnant individuals carrying at least one HbS allele will be included in the study to collect the umbilical cord blood of the child at birth. Collected cells will be used anonymously for genetic and bioexperimental laboratory research, aiming to develop autologous gene therapy for sickle cell disease.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sickle Cell Disease

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pregnant women, giving birth at CHSF and consenting to the collect and study of placental blood after delivery * Age 18 to 45 years * Biological testing of the participant includes hemoglobin electrophoresis and shows at least one HbS allele Exclusion Criteria: * Lack of written consent * Minors (not 18 years old) or under guardianship * Diseases : HIV, Hepatitis B, Hepatitis C or HTLV (Human T Leukemia Virus).

Locations (1)

CHSF

Corbeil-Essonnes, France

Outcomes

Primary Outcomes

Number of samples with HbS/HbS genotype

Measured by DNA sequencing

Time frame: 3 years

Secondary Outcomes

Number of samples with bio-experimental data

Consisting of cellular characterization, transduction and cell processing data

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.